LAM
VRTX icon

L2 Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

L2 Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-989
Closed -$460K – 266
2024
Q3 		$460K Sell
989
-664
-40% -$319K 0.12% 120
2024
Q2 		$775K Sell
1,653
-741
-31% -$322K 0.23% 82
2024
Q1 		$1M Buy
2,394
+673
+39% +$285K 0.33% 75
2023
Q4 		$700K Buy
1,721
+748
+77% +$276K 0.29% 78
2023
Q3 		$1.05M Sell
973
-2,176
-69% -$761K 0.49% 59
2023
Q2 		$940K Buy
3,149
+150
+5% +$50.5K 0.46% 60
2023
Q1 		$945K Buy
2,999
+1,515
+102% +$454K 0.52% 58
2022
Q4 		$429K Hold
1,484
– – 0.27% 83
2022
Q3 		$430K Buy
1,484
+214
+17% +$61.6K 0.3% 81
2022
Q2 		$358K Buy
+1,270
New +$340K 0.26% 92
2021
Q1 		– Sell
-2,904
Closed -$686K – 90
2020
Q4 		$686K Buy
2,904
+459
+19% +$105K 0.47% 59
2020
Q3 		$665K Buy
+2,445
New +$675K 0.54% 53

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

L2 Asset Management's VRTX Position: Q4 2024 in Review

L2 Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 989 shares — an estimated $460K sold.

L2 Asset Management first reported a position in VRTX in Q3 2020 and held it in 12 quarters. The position peaked at $1.05M in Q3 2023. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • L2 Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • L2 Asset Management sold 989 Vertex Pharmaceuticals shares in Q4 2024, an estimated $460K.
  • L2 Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 12 quarters.
  • L2 Asset Management's Vertex Pharmaceuticals position peaked at $1.05M in Q3 2023.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on L2 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.